Lisdexamfetamine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01255 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 49 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | specific developmental disorder | KG + DL |
| 2 | faciodigitogenital syndrome | KG + DL |
| 3 | chondromyxoid fibroma | KG + DL |
| 4 | autosomal dominant cerebellar ataxia | KG + DL |
| 5 | cerebellar ataxia | KG + DL |
| 6 | spinocerebellar degeneration with slow eye movements | KG + DL |
| 7 | trichotillomania | KG + DL |
| 8 | transient tic disorder | KG + DL |
| 9 | narcolepsy | KG + DL |
| 10 | narcolepsy, susceptibility to | KG + DL |
| 11 | manic bipolar affective disorder | KG + DL |
| 12 | hypersomnia (disease) | KG + DL |
| 13 | circadian rhythm sleep disorder | KG + DL |
| 14 | proximal 16p11.2 microdeletion syndrome | KG + DL |
| 15 | obesity disorder | KG + DL |
| 16 | Creutzfeldt-Jakob disease | KG + DL |
| 17 | Balo concentric sclerosis | KG + DL |
| 18 | restless legs syndrome | KG + DL |
| 19 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 20 | hypervitaminosis | KG + DL |
| 21 | schizophrenia | KG + DL |
| 22 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 23 | atypical glycine encephalopathy | KG + DL |
| 24 | myopia 26, X-linked, female-limited | KG + DL |
| 25 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 26 | myopia X-linked | KG + DL |
| 27 | communication disorder | KG + DL |
| 28 | developmental disorder of mental health | KG + DL |
| 29 | fetal nicotine spectrum disorder | KG + DL |
| 30 | stereotypic movement disorder | KG + DL |
| 31 | narcolepsy without cataplexy | KG + DL |
| 32 | narcolepsy-cataplexy syndrome | KG + DL |
| 33 | X-linked adrenoleukodystrophy | KG + DL |
| 34 | syndromic myopia | KG + DL |
| 35 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 36 | hydranencephaly (disease) | KG + DL |
| 37 | focal, segmental or multifocal dystonia | KG + DL |
| 38 | myoclonus, familial | KG + DL |
| 39 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 40 | megaconial type congenital muscular dystrophy | KG + DL |
| 41 | disorder of peroxisomal alpha-, beta- and omega-oxidation | KG + DL |
| 42 | channelopathy-associated congenital insensitivity to pain, autosomal recessive | KG + DL |
| 43 | insomnia (disease) | KG + DL |
| 44 | central nervous system disease | KG + DL |
| 45 | obsolete hypertelorism (disease) | KG + DL |
| 46 | mesial temporal lobe epilepsy with hippocampal sclerosis | KG + DL |
| 47 | multiple system atrophy | KG + DL |
| 48 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | KG + DL |
| 49 | variably protease-sensitive prionopathy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.